How AstraZeneca deal would benefit Pfizer

3:19 PM ET Mon, 28 April 2014

CNBC's Eamon Javers takes a close look at Pfizer's $100 billion bid for AstraZeneca. The deal would elevate Pfizer's cancer drug pipeline while giving them enormous tax savings.